期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼或紫杉醇-卡铂治疗肺腺癌

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
下载PDF
导出
摘要 1文献来源 Mok TS, Wu YL, Thongprasert S, et at.Gefitinib or Carboplatin-Paclitaxel in pulmonaryadenocarcinoma [J]. N Engl J Med, 2009,361（10）：947-957.
作者 黄诚 徐崇锐
机构地区 福建省肿瘤医院肿瘤内科 广东省人民医院肿瘤中心广东省肺癌研究所广东省医学科学院
出处 《循证医学》 CSCD 2011年第1期31-33,共3页 The Journal of Evidence-Based Medicine
关键词 癌 非小细胞肺 表皮生长因子受体 酪氨酸激酶抑制剂 敏感突变 化疗 靶向治疗 carcinoma, non-small cell lung epidermal growth factor receptor tyrosine kinase inhibitor sensitive mutations chemotherapy target therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Mitsudomi T,Morita S,Vatabe Y,et al.Gefitinib vereus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):An open label,randomised phase 3 trial[J].Lancet Oncol,2010,11(2):121-128.
  • 2Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388.
  • 3Zhou C.Efficacy results from the randomised phase 3 OPTIMAL (CTONG 0802) study comparing first-line Erlotinib versus Carboplatin (CBDCA) plus Gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations.Program and abstracts of the 35th European Society of Medical Oncology Congress; October 8-12,2010; Milan,Italy.Abstract LBA13.
  • 4Gridelli C,Butts C,Ciardiello F,et al.Intemational multicenter randomized phase Ⅲ study of first-line Erlotinib (E) followed by second-line Cisplatin plus Gemcitabine (CG) versus first-line CG followed by second-line in advanced non-small cell lung cancer (aNSCLC):The TORCH trial[J].J Clin Oncol,2010,28(15suppl):abstr 7508.
  • 5Lee S,Rudd R,Khan I,et al.TOPICAL; Randomized phase Ⅲ trial of Erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy[J].J Clin Oncol,2010,28(15suppl):abstr 7504.
  • 6Bang Y,Kwak EL,Shaw AT,et al.Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2010,28(18s):abstr 3.
  • 7Han SW,Kim TY,Hwang PG,et al.Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with Gefitinib[J].J Clin Oncol,2005,23(11):2493-2501.
  • 8Hirsch FR,Varella-Garcia M,Bunn FA Jr,et al.Molecular predictors of outcome with Gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small-cell lung cancer[J].J Clin Oncol,2006,24 (31):5034-5042.
  • 9Yang CH,Yu CJ,Shih JY,et al.Specific EGFR mutations predict treatment outcome of stage Ⅲ/Ⅳ chemonaive NSCLC patients receiving first-line Gefitinib monotherapy[J].J Clin Oncol,2008,26(16):2745-2753.
  • 10Cappuzzo F,Ligorio C,Janne PA,et al.Prospective study of Gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer:The ONCOBELL trial[J].J Clin Oncol,2007,25(16):2248-2255.
循证医学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部